Skip to main content


Night Splinting for Carpal Tunnel (3.24.2023)

Mar 24, 2023

Dr. Jack Cush reviews the news and journal articles from the past 2 weeks on  This week reviews clinical associations with SS-A, a new biomarker for SSc-ILD and cancer screening for myositis patients.

  1. 29 pts w/ PsA Sine Psoriasis: 16F/13M, mean age 45 yrs w/

Read Article

Spondyloarthritis Innovations

Mar 21, 2023

The second day of RheumNow Live 2023 ended with a focus on axial spondyloarthritis, especially on the evaluation of the definition of the disease, the inheritance of it, and of course the treatment of it.

Read Article
Future treatment for #AxSpA ? Promising data for #Bimekizumab Inhibits IL-17 A and F #RNL2023
No significance difference in radiographic progression in patients with IL17-TNF , BY Atul Deodhar #RNL2023 ⁦@RheumNow⁩
SURPASS: SEC vs ADA for axSpA Outcome: %pts with no radiographic progression Not benefit- Secukinumab not better than adalimumab Though negative study, in all groups the progression was very low (<1 mSASS) - both interventions did well! @RheumNow #RNL2023
Late breaking ACR abstract '22 SURPASS study (H2H TNFi vs IL17 in AS radiographic progression.) Primary endpoint was not met. However, Dr. Deodhar's take away: spinal radiographic progression over 2 years is very low despite high disease activity in both txs! #RNL2023 @RheumNow
Bimekizumab is a dual IL-17A and IL-17F inhibitor, for nr-axSpA and AS - it works but is it different from existing IL-17i? - appears to work well in TNFi-inadequate responders - are TNFi-IR pts immunologically different? niche category for IL-17A and F use? @RheumNow #RNL2023
#RNL2023 Year in Review New Drugs in Old Disease? GCA - Tocilizumab (GiACTA ), Secikinumab (TitAIN), Mavrilimumab (GM-CSFr mAb) PMR - Sarilumab (SAPHYR), TCZ (PMR-Spare, SEMAPHORE), Tofacitinib (EAST PMR) @RheumNow
An exciting year and time for GCA and PMR treatment! - Tocilizumab (IL-6i) - Secukinumab (IL-17i) - Sarilumab (IL-6i) - Mavrilimumab (GM-CSF receptor mAb) - Tofacitinib (JAKinib) @RheumNow #RNL2023
#RNL2023 Year in Review BE COMPLETE: P3 trial Bimekizumab for PsA in TNF inadequate responses at 16 weeks 160 mg BKZ SQ q4w vs PBO ACR50 43%, PBO 7% PASI 1000: BKZ 58.5% vs PBO 4.5% Safety: oral candidiasis: 2.6% BKZ vs PBO 0% @RheumNow

Bimekizumab Maintains Improvements in Efficacy Endpoints and has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies

Sponsored by UCB
Mar 09, 2023

This poster reports key efficacy outcomes such as ASAS40 response at Week 16 and Week 52 for the overall population and in TNFi-naïve and TNFi-experienced patients. The poster also discusses patients treated with BKZ achieving low disease activity (LDA) based on the ASDAS scores, objective

Read Article

Does Biologic Treatment in Psoriasis Reduce the Risk of Psoriatic Arthritis?

Mar 07, 2023

Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.

There has been considerable debate whether

Read Article

Psoriatic Arthritis: Depressing News on Second- and Later-Line Treatments

MedPage Today
Feb 28, 2023

Most patients with psoriatic arthritis (PsA) failed to achieve low disease activity after switching from one targeted therapy to another, real-world data from Scandinavian registries indicated.

Moreover, patients became increasingly less likely to see substantial symptom improvement

Read Article

GRAPPA Recommendations for Treating Enthesitis in Psoriatic Arthritis

Feb 06, 2023

GRAPPA has provided new, evidence based updates to the management of enthesitis in patients with psoriatic arthritis (PsA), affecting at least 30% of PsA patients and is associated with more severe disease, x-ray damage, and poorer outcomes. 

Read Article

Simon Says “Don’t Do This” (1.27.2022)

Jan 27, 2023

Dr. Jack Cush reviews this week’s journal articles, focuses on studies that should not have been done and responds to viewer questions in Ask Cush Anything.

  1. "Dry Synovitis" exist in juvenile arthritis pts? Study of 12 DS pts, says its different from Poly #JIA; onset 6.1 yrs

Read Article
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
Phase III Trials Back Bimekizumab for Spondyloarthritis Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said.
Bimekizumab in Active Psoriatic Arthritis - BE COMPLETE study

Bimekizumab in Active Psoriatic Arthritis - BE COMPLETE study

Jan 11, 2023

BE COMPLETE is published, showing that bimekizumab (BMK), a selective dual inhibitor of interleukin (IL)-17F and IL-17A, results in superior improvement in both skin and joint outcomes in psoriatic arthritis (PsA) patients who have previously failed treatment with a tumour necrosis factor-α (

Read Article

2022 Rheumatology Year in Review (1-6-2023)

Jan 06, 2023

Dr. Jack Cush reviews the best of 2022 in Rheumatology - highlights on new drug indications, breakthrough lupus therapies, new biosimilars and the multivitamin letdown.

Read Article

2022 Rheumatology Year in Review

Jan 05, 2023

2022 was a year of recovery, discovery, and some losses.  While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.

Read Article

Best of 2022: New Updated GRAPPA Psoriatic Arthritis Recommendations

Dec 26, 2022

The GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains" - peripheral arthritis, axial disease, enthesitis,

Read Article
Get the Skinny on Bimekizumab in PsA Dr. Janet Pope discusses abstract presented at #ACR22.

Inflammatory Arthritis and Hidradenitis Suppurativa

Dec 09, 2022

Hidradenitis suppurativa (HS) (also called acne inversa), is a chronic inflammatory skin disorder affecting apocrine gland-bearing skin in the axillae, groin, and under the breasts and is characterised by persistent or 

Read Article

The Top 10 Research Priorities in Psoriatic Arthritis

Dec 06, 2022

A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA).

A series of surveys were initated by the British Psoriatic Arthritis Consortium (BritPACT) and funded by the James Lind Alliance (JLA

Read Article